NOVEL Health Strategies team is presenting 10 studies at ISPOR Annual Meeting in Philadelphia, PA on market access strategy, pricing and health economic and outcomes research trends.
One of NOVEL's presentations was also selected for PODIUM PRESENTATION.
These studies were led by Novel Health team and are good examples of wide breadth and depth of our expertise.
In-person replays of all presentations are available upon request
PHP 167: TRENDS IN USE OF HEALTH ECONOMIC EVIDENCE FOR DEVELOPING CLINICAL GUIDELINES
PSS 32: PATIENT REPORTED OUTCOMES IN GLAUCOMA A SYSTEMATIC REVIEW
PCN 53: SYSTEMATIC REVIEW OF EPIDEMIOLOGY AND BURDEN OF PANCREATIC CANCER
PCN 54: SYSTEMATIC REVIEW OF EPIDEMIOLOGY AND BURDEN OF CUTANEOUS T-CELL LYMPHOMA
PHP 109: OVERVIEW AND IMPORTANCE OF NUB PROCESS FOR MARKET ACCESS OF IN-PATIENT DRUGS AND DEVICES IN GERMANY
PHP 14: IMPACT OF 2014 ESSENTIAL HEALTH BENEFIT BENCHMARK PLANS ON US MANAGED CARE
PHP 105: IMPACT OF NEW CHANGES DUE TO AFFORDABLE CARE ACT ON US MARKET ACCESS
PHP 101: COMPARATIVE EFFECTIVENESS, APPROVAL RATES AND PRICING OF DRUGS WITH FDA'S BREAKTHROUGH THERAPY DESIGNATIONS
PSY 75: COMPARISON OF ULTRA ORPHAN AND CANCER DRUG PRICING IN THE US AND THE UK